ICD-10 E78.5: Hyperlipidemia Billing and Coding Guide

Hyperlipidemia is one of the most prevalent chronic conditions in the United States, affecting approximately 94 million adults with total cholesterol above 200 mg/dL. ICD-10 code E78.5 classifies hyperlipidemia that has not been further specified, serving as a starting point that should evolve into more precise coding as the clinical picture becomes clear.

E78.5 as a Starting Point, Not an Endpoint

E78.5 is appropriate for the initial visit when a patient’s lipid abnormality has been identified but not yet characterized by lab results. After a lipid panel is obtained and results are available, the diagnosis should be updated to the specific type. E78.00 covers pure hypercholesterolemia when only cholesterol values are elevated. E78.1 covers pure hypertriglyceridemia. E78.2 covers mixed hyperlipidemia when both cholesterol and triglycerides are above normal ranges.

Practices that continue using E78.5 for established patients with known lipid patterns miss an opportunity for more accurate clinical documentation and may face payer edits. Several commercial payers now flag E78.5 on claims that include specialty lipid management codes or expensive medication authorizations, requiring more specific diagnosis information before processing the claim.

Lab Ordering and Documentation

The standard lipid panel (CPT 80061) includes total cholesterol, HDL, LDL (calculated or direct), and triglycerides. This panel is the foundation for hyperlipidemia diagnosis and monitoring. When ordering the lab, the diagnosis code determines medical necessity and coverage.

For patients with an established E78 diagnosis, use the specific E78 code as the ordering diagnosis. For screening in patients without a known lipid disorder, use Z13.220 (encounter for screening for lipoid disorders). Medicare covers lipid screening once every 5 years for beneficiaries without a lipid diagnosis and more frequently for monitoring diagnosed conditions.

Advanced lipid testing (Lp(a), apoB, LDL particle number) requires additional clinical justification beyond the standard E78 codes. Document the clinical reason for advanced testing, such as family history of premature cardiovascular disease or discordance between standard lipid markers and cardiovascular risk assessment. Without this documentation, advanced lipid tests are frequently denied.

Statin Therapy and Medication Coding

Statin medications are first-line therapy for most patients with hyperlipidemia. Generic statins (atorvastatin, rosuvastatin, simvastatin) rarely require prior authorization. Brand-name statins and combination products (ezetimibe/simvastatin) may require step therapy documentation showing generic statin trial first.

When patients experience statin intolerance, document the specific adverse effects, the statin tried, the dose, and the duration before discontinuation. This documentation supports authorization for alternative therapies and creates the clinical trail needed for eventual PCSK9 inhibitor approval if needed. Code the adverse effect using the appropriate T code series (T46.6X5A for adverse effect of antihyperlipidemic drugs) alongside E78.5 to flag the intolerance in the claims record.

Ezetimibe (Zetia) is typically the second-line agent after statin intolerance or insufficient response. Most payers cover generic ezetimibe without prior authorization when used with a statin or after documented statin intolerance. The combined use of statin plus ezetimibe supports the clinical pathway toward PCSK9 inhibitor approval when LDL remains above goal.

PCSK9 Inhibitor Authorization

PCSK9 inhibitors (evolocumab, alirocumab) represent the highest-cost lipid-lowering medications, with list prices exceeding $5,000 per year. The prior authorization process is correspondingly rigorous and requires careful documentation of the clinical pathway.

The standard authorization requirements include a confirmed diagnosis of ASCVD (atherosclerotic cardiovascular disease) or heterozygous familial hypercholesterolemia, documentation of maximum tolerated statin therapy with specific dose and duration, an LDL level above the target threshold (typically 70 mg/dL for ASCVD patients or 100 mg/dL for primary prevention), and trials of at least one additional lipid-lowering agent (ezetimibe) with documented failure to reach goal.

Diagnosis coding for PCSK9 authorization should use the most specific E78 code available plus any ASCVD codes (I25.10 for coronary artery disease, I63.9 for stroke history, I73.9 for peripheral vascular disease) that establish cardiovascular risk. E78.5 alone rarely satisfies PCSK9 authorization criteria because payers need to see the specific lipid pattern to evaluate treatment appropriateness.

Cardiovascular Risk and Value-Based Coding

Hyperlipidemia codes are integral to cardiovascular risk profiling in value-based care models. Practices participating in ACOs, MIPS, or commercial value-based contracts use lipid diagnosis codes as part of the hierarchical condition category (HCC) risk adjustment process.

E78.5 has less risk adjustment weight than more specific codes. E78.01 (familial hypercholesterolemia) carries additional weight because it represents a higher-severity condition requiring more intensive management. Accurate coding that reflects the true clinical complexity of the patient’s lipid disorder ensures appropriate risk-adjusted payments.

MIPS quality measures related to statin therapy for cardiovascular prevention require accurate hyperlipidemia coding for measure denominators. Measure 438 tracks statin prescribing for patients with clinical ASCVD, while preventive care measures address statin use for primary prevention in high-risk patients. Both depend on correct ICD-10 coding to identify eligible patients.